<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004638</url>
  </required_header>
  <id_info>
    <org_study_id>D5780C00005</org_study_id>
    <nct_id>NCT03004638</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease</brief_title>
  <official_title>A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of
      MEDI6012 in subjects with stable atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety,
      Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects
      with Stable Atherosclerotic Cardiovascular Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Actual">November 2, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6012</measure>
    <time_frame>Day 1 to Day 71 (Cohorts 1-3); Day 1 to Day 66 (Cohort 4)</time_frame>
    <description>Measured by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline adjusted area under the curve</measure>
    <time_frame>Time 0 to 96 hours post dose 3</time_frame>
    <description>Baseline adjusted HDL-C, HDL-CE, and CE AUC will be calculated using the trapezoidal rule. Statistical comparison between treatment groups with placebo groups combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Cmax</measure>
    <time_frame>Day 1 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity rate</measure>
    <time_frame>Day 1 to Day 71 (Cohorts 1-3); Day 1 to Day 66 (Cohort 4)</time_frame>
    <description>ADA incidence rate and titer will be tabulated for each treatment group. Samples confirmed positive for ADA will be tested and analyzed for nAB titer and summarized similarly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline adjusted area under the curve</measure>
    <time_frame>Time 0 to 96 hours post last dose</time_frame>
    <description>Baseline adjusted Apolipoprotein A1,LDL, and Apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Tmax</measure>
    <time_frame>Day 1 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 AUC</measure>
    <time_frame>Day 1 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Terminal Half life</measure>
    <time_frame>Day 1 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 1 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 2 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 3 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 4 dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6012</intervention_name>
    <description>MEDI6012</description>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-childbearing potential

          -  Diagnosis of stable atherosclerotic CVD

          -  Currently receiving a stable dose of Statin

        Exclusion Criteria:

          -  Unstable cardiovascular condition within 3 months of screening

          -  Elective arterial revascularization with in the past month

          -  Any planned arterial revascularization

          -  Body mass index &lt;18 or &gt;45

          -  Clinically significant ECG that may interfere with the interpretation of serial ECG
             and QT interval changes at screening

          -  Chronic kidney disease defined by estimated glomerular filtration rate of less than 30
             mL/mim/1.73m2

          -  Triglycerides greater than 500 mg/dL, LDL-C greater than 160 mg/dL, or HDL-C greater
             than 60 for males, or 65 for females

          -  Clinically significant vital sign abnormalities

          -  Genetic disorder of cholesterol metabolism

          -  History of overt liver disease

          -  Poorly controlled endocrine disorder (Diabetes or Thyroid disorder)

          -  Current or recent use of systemic corticosteroids

          -  Recent or ongoing infection or febrile illness

          -  History of active malignancy within 5 years

          -  History of alcohol or recreational substance abuse in the past 6 months

          -  Concurrent enrollment in another clinical study of any investigational drug therapy or
             use of any biologicals within 6 months prior to screening or within 5 half-lives of an
             investigational agent or biologic, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>CAD</keyword>
  <keyword>Atherosclerotic Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

